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ABSTRACT
Candidaemia is increasingly important in intensive care units (ICUs). Compared with Candida albicans
fungaemia, the impact of C. glabrata fungaemia on ICU patients is not well-known. The aim of this study
was to investigate the clinical features, the antifungal susceptibility and the treatment outcomes of
C. glabrata fungaemia in ICU patients. The medical records of ICU patients with candidaemia between
2000 and 2005 were reviewed retrospectively, and antifungal susceptibility testing was performed for
isolates of C. glabrata. Among 147 episodes of candidaemia occurring in adult ICUs, C. glabrata was the
second most common species and accounted for 45 (30%) episodes of candidaemia. The incidence of
C. glabrata fungaemia was 1.3 ⁄ 1000 ICU admissions. Fluconazole resistance was found in 11% of
C. glabrata isolates. The 30-day all-cause mortality rate was 58%. Therapeutic regimens containing
amphotericin B were associated with better outcome. Despite higher fluconazole resistance, C. glabrata
candidaemia was not associated with greater mortality than non-glabrata candidaemia in the ICU setting.
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INTRODUCTION
Bloodstream infection caused by Candida spp. is
increasingly important in critical care [1]. In the
USA, Candida spp. are the third most common
cause of nosocomial bloodstream infection in
intensive care units (ICUs), and are associated
with high mortality [1]. The proportion of non-
albicans Candida spp. causing candidaemia has
increased during recent decades, and it is consid-
ered that frequent use of fluconazole has played a
major role in this increase [2–4]. Of the non-
albicans Candida spp., Candida glabrata has
emerged as an important cause of fungaemia
in the ICU [4]. C. glabrata has unique biological
and genetic characteristics compared with other
Candida spp., in that it is smaller in morphology,
cannot form pseudohyphae, and has a haploid
rather than a diploid genome [5,6].
Despite these differences between C. albicans
and other Candida spp., the question of whether
C. glabrata fungaemia differs in clinical features
and outcome from fungaemia caused by other
Candida spp. remains unclear. Although several
studies have examined the epidemiology or out-
come of candidaemia in the ICU setting, data
focused on C. glabrata are limited [2,4,7–9]. The
present study retrospectively reviewed the clini-
cal features and treatment outcomes of C. glabrata
fungaemia occurring in ICU patients during
2000–2005 in our hospital. Antifungal susceptibil-
ity testing of C. glabrata isolates was also
performed.
MATERIALS AND METHODS
Patients
All patients with Candida bloodstream infection between
January 2000 and December 2005 were identified from the
records of the microbiology laboratory at National Taiwan
University Hospital, a tertiary-care medical centre in Taiwan.
Episodes of candidaemia developing >48 h after ICU admis-
sion were considered to have occurred in the ICU and were
included in the analysis. Episodes of candidaemia that
occurred in patients in the paediatric ICU were excluded. An
episode of C. glabrata fungaemia was recorded when at least
one blood culture was positive for C. glabrata. Fungaemia
occurring in the same patient during the same hospital
admission period was counted as only one episode. Medical
records were reviewed retrospectively to collect data
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concerning demographical characteristics, treatment and out-
come. Predisposing factors reported previously to be associ-
ated with candidaemia were recorded [10].
Antifungal susceptibility testing
C. glabrata isolates were stored in the mycology laboratory at
)70C in trypticase soy broth containing glycerol 15% v ⁄v.
Before susceptibility testing, the isolates were passaged twice
on potato dextrose agar. Antifungal susceptibility testing was
performed using the reference broth microdilution method
according to CLSI guidelines [11]. The tested concentrations of
antifungal agents ranged from 0.03 to 64 mg ⁄L. Two reference
strains, Candida parapsilosis ATCC 22019 and Candida krusei
ATCC 6258, were used as quality control strains. MICs were
determined after incubation for 48 h. Antifungal susceptibil-
ities were interpreted according to CLSI guidelines and other
recommendations [10,11].
Statistical analyses
Categorical variables were assessed using Fisher’s exact test or
chi-square tests, as appropriate, while the probability of
survival was estimated using the Kaplan–Meier method;
p values <0.05 were considered to be statistically significant.
RESULTS
Epidemiological and clinical features
During the 6-year period from January 2000 to
December 2005, there were 147 episodes of can-
didaemia in the adult ICUs of the hospital, and
these accounted for 27% of the total episodes of
candidaemia in the hospital. Among the episodes
of ICU candidaemia, C. glabrata was the second
most common causative species, and accounted
for 30% of episodes (Table 1). The incidence of
candidaemia in ICUs during the study period was
4.3 ⁄ 1000 ICU admissions, or 5.9 ⁄ 10 000 patient-
days. For C. glabrata fungaemia, the incidence was
1.3 ⁄ 1000 ICU admissions. The incidence trends
are shown in Fig. 1. The incidence of C. glabrata
fungaemia in the ICUs ranged from 0.59 to
2.17 ⁄ 1000 ICU admissions, and peaked during
2003.
The clinical features of cases of C. glabrata
fungaemia in ICUs are summarised in Table 2.
Most of the patients who developed C. glabrata
fungaemia in an ICU had multiple underlying
illnesses (Table 2). On average, each patient expe-
rienced failure of 2.5 organs. In addition to
underlying disease, common risk-factors included
previous use of antimicrobial agents, intravascu-
lar devices, parenteral nutrition, previous abdom-
inal surgery and previous fluconazole exposure.
Antifungal susceptibilities
Overall, 60% of C. glabrata isolates were suscep-
tible to fluconazole (MIC £8 mg ⁄L), 29% were
susceptible ⁄dose-dependent (MIC 16–32 mg ⁄L),
and 11% were resistant to fluconazole
(MIC >32 mg ⁄L). However, there was no associ-
Table 1. Species distribution of 147 episodes of candida-
emia occurring in adult intensive care units
Species Number of episodes (%)
Candida albicans 57 (39)
Candida glabrata 45 (30)
Candida tropicalis 26 (18)
Candida parapsilosis 12 (8)
Candida guilliermondii 3 (2)
Others 4 (3)
Fig. 1. Incidence of candidaemia and Candida glabrata
fungaemia in adult intensive care units (ICUs).
Table 2. Characteristics of 45 episodes of Candida glabrata
fungaemia in adult intensive care units (ICUs)
Characteristic Value
Age (mean years ± SD) 70 ± 14
Gender, male ⁄ female 24(53%) ⁄ 21(47%)
APACHE II score at ICU admission (mean ± SD) 24.3 ± 8.7
ICU specialty, medical ⁄ surgical 28 (62%) ⁄ 17(38%)
Onset of fungaemia: median hospital days
Median ICU days
32
13
Organ failure or systemic diseases (%)
Respiratory failure with mechanical ventilation 93
Renal failure requiring dialysis 53
Hepatic dysfunctiona 20
Malignancy 31
Autoimmune disease 11
Diabetes 38
Risk-factors (%)
Previous antimicrobial useb 98
Previous fluconazole useb 31
Chemotherapyb 11
Systemic steroidsb 29
Neutropeniac 2
Receipt of parenteral nutrition 53
Intravascular devices 96
Previous abdominal surgery 36
APACHE, acute physiology and chronic health evaluation score.
aClass B or C in Child–Pugh classification.
bReceipt of antibiotics, fluconazole, chemotherapy or systemic steroids during the
previous 30 days.
c<500 neutrophils ⁄mm3 for >48 h during the previous 7 days.
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ation between the presence or absence of fluco-
nazole resistance and 30-day mortality (p 0.113).
Amphotericin B and caspofungin were highly
active against C. glabrata (100% susceptible), with
MICs of £1mg ⁄L and £2 mg ⁄L, respectively.
Treatment and outcome
Forty of 45 episodes of C. glabrata fungaemia were
treated with various regimens of antifungal
agents. Of the five untreated episodes, four
involved death of the patient before diagnosis,
and one patient was treated only by removal of a
central venous catheter. Among the 40 treated
episodes, antifungal agents were initiated at a
mean of 2 days after blood culture was per-
formed, with 26 (65%) of 40 patients receiving
antifungal therapy within 48 h. The treatment
regimens and outcomes are listed in Table 3.
Fluconazole was the initial antifungal agent used
in 97.5% of episodes. The most common treat-
ment regimen, used in 52.5% of episodes, com-
prised initial treatment with fluconazole followed
by a switch to amphotericin B after identification
of the infecting species as C. glabrata. Fluconazole
alone was used in 40% of episodes. Amphoteri-
cin B-containing regimens, used in 55% of epi-
sodes, were associated with lower mortality than
were regimens without amphotericin B (p 0.048,
chi-square test). The 30-day all-cause mortality
rate was 58%. Fig. 2 compares the survival of
patients with fungaemia caused by C. glabrata and
that caused by other Candida spp.; there was no
significant difference in survival between the two
groups (p 0.688, log-rank test).
DISCUSSION
Candidaemia is an important nosocomial blood-
stream infection among ICU patients [9,10].
C. glabrata has accounted for 10–30% of cases of
candidaemia in ICUs in various reports, and an
increasing incidence has been noted in some areas
[4,7,12]. In the present study, C. glabrata was the
second most common cause of candidaemia and
accounted for 30% of the episodes of candidaemia
in adult ICUs. The annual incidence of C. glabrata
fungaemia varied during the study period (Fig. 1)
and, in contrast to a previous study [4], a
continuously increasing incidence of C. glabrata
fungaemia in ICUs was not observed. It is not
clear why the incidence of C. glabrata fungaemia
peaked in 2003 and then declined between 2003
and 2005. However, consumption of fluconazole
in the hospital also peaked in 2003 and decreased
in the following 2 years (data not shown).
Several previous studies have thoroughly inves-
tigated the risk-factors associated with invasive
candidiasis and candidaemia [9,10]. Susceptible
hosts and existing portals of entry are two
major risk-factors for developing candidaemia.
The disease patterns and risk-factors associated
previously with candidaemia [10] were also com-
monly seen in the patients with C. glabrata funga-
emia (Table 2). Most of the patients had multiple
organ dysfunction and, because of the ICU setting
of this study, the proportion of patients with
respiratory failure was also high. However, the
proportions of patients on dialysis (53%) and with
malignancy (31%) were higher than would be
expected among ICU patients; a possible explana-
tion could be the existence of a suitable portal of
entry. The gut and the skin are thought to be the
two major portals of entry, and the latter has been
implicated in the pathogenesis of catheter-related
Table 3. Treatment regimens for Candida glabrata funga-
emia in adult intensive care units and 30-day all-cause
mortality rate
Treatment regimens
(treated episodes, n = 40)
Episodes of
fungaemia, n (%)
Deaths within 30
days, n (%)
Fluconazole alone 16 (40) 11
Fluconazole followed by amphotericin B 21 (52.5) 9
Fluconazole followed by caspofungin 2 (5) 2
Caspofungin followed by amphotericin B 1 (2.5) 0
Regimens without amphotericin B 18 (45) 13 (72)a
Regimens containing amphotericin B 22 (55) 9 (41)a
ap 0.048 (chi-square test).
Fig. 2. Overall survival of patients in adult intensive care
units with Candida glabrata fungaemia (n = 45) and funga-
emia caused by other Candida spp. (n = 102).
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candidaemia [13]. In the present study, more than
half of the patients with malignancy suffered from
cancer of the gastrointestinal tract, and these
patients often had long-term central catheters
(Port-A cath or double lumen catheter). The
underlying diseases and risk-factors found in a
high percentage of patients (Table 2) reflect a
picture of immunocompromised hosts with suit-
able portals of entry. Exposure to fluconazole had
occurred in 31% of cases, and exposure to azoles
has been considered to contribute to species shift
to non-albicans Candida spp. in many previous
studies [3,14,15].
Compared with Candida albicans, C. glabrata has
been found to be relatively resistant to azole
antifungal agents [16–18]. However, it remains to
be clearly established whether bloodstream iso-
lates from ICU patients are associated with higher
azole resistance. In the present study of ICU
patients, 11% of bloodstream isolates were resis-
tant to fluconazole, which is similar to the figure
of 14% revealed by a national antifungal resis-
tance surveillance study in Taiwan in which
C. glabrata isolates were not restricted to ICU
patients [19]. Caspofungin and amphotericin B
still remained highly active against the C. glabrata
isolates from ICU patients in the present study.
Fluconazole resistance is a great concern in the
management of patients with C. glabrata candida-
emia, particularly as prompt susceptibility testing
is not always available. Fluconazole and ampho-
tericin B were considered to have similar treat-
ment outcomes in several previous studies of
non-neutropenic patients with candidaemia
[20–22]. However, this finding cannot be general-
ised to all patients, especially critically-ill ICU
patients, and these studies focused mainly on
C. albicans candidaemia. One study has reported
similar mortality rates among patients with
C. glabrata candidaemia who received fluconazole
rather than other antifungal therapy, but this
study included all hospitalised patients in the
analysis [23]. In the present study, all of
the patients were hospitalised in the ICU,
and amphotericin B-containing regimens were
revealed to be associated with significantly lower
mortality. The Infectious Diseases Society of
America (IDSA) has suggested treating serious
cases of C. glabrata candidaemia with amphoter-
icin B or caspofungin, rather than with fluconaz-
ole [24,25]. The differences in study designs
(retrospective without selection in the present
study, as compared with prospective in a selected
population of patients in the randomised trials)
also contribute to different outcomes.
The outcome of ICU patients with candidaemia
is poor, with mortality ranging from 47% to 58%
in previous studies [1,10]. Despite this well-estab-
lished impact of candidaemia on ICU mortality,
data concerning the impact of C. glabrata candi-
daemia on ICU patients are scarce. In theory,
C. glabrata has higher resistance to azoles, and
may therefore be associated with higher mortality
as compared with non-glabrata candidaemia.
However, a previous study reported that the
mortality rates were similar among patients
with C. glabrata or non-glabrata candidaemia,
although this previous study was not focused
specifically on ICU patients [23]. In the present
study, the all-cause 30-day mortality rate of ICU
patients with C. glabrata fungaemia was 58%. No
significant difference between the survival of
patients with C. glabrata and those with non-
glabrata candidaemia in ICUs was found, with
C. glabrata and non-glabrata candidaemia having a
similar impact on 30-day survival rates.
The present study had several limitations. First,
the ICU patients were critically-ill, and many
factors contributed to their death. It was difficult
to clarify the contribution of fungaemia to mor-
tality, and all-cause mortality was therefore cho-
sen, rather than fungaemia-related death, for
outcome analyses. However, the choice of 30 days
for the mortality analysis was arbitrary. Second,
the choice of antifungal agent did not follow a
consistent protocol during the study period, and
depended mainly on the clinical judgement of the
critical care specialists. Selection biases were
prominent problems. Third, because of the retro-
spective design of this study, it was not possible
to obtain the APACHE II score at the time of
onset of fungaemia, and therefore it was not
possible to adjust for the influence of underlying
disease.
In conclusion, this study confirmed that C. glab-
rata and non-glabrata candidaemia resulted in
similar outcomes among ICU patients, despite the
differences in biology, antifungal susceptibilities
and genetics of these two groups of organisms.
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